Inveltys (loteprednol etabonate nano-suspension 1%) - Kala Pharma
Inveltys: Patent expiry related to MPP technology in 2033 (28th Annual Oppenheimer Healthcare Conference, Kala Pharma) Mar 22, 2018 
Patent Dry Eye Disease • Ophthalmology
https://www.veracast.com/webcasts/opco/healthcare2018/48207276815.cfm?0.399411302329
 
Mar 22, 2018
 
 
2a20f6ec-42c9-4e37-96dc-2df06c8b3072.jpg